← 返回

共刺激结构域促进 CAR-T 细胞抗肿瘤疗效的分子机制

英文原题:Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

查看英文原题

Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.

PubMed 2024/07/18(内容时间) Biochem Pharmacol Q1 · IF 6.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CAR工程化T细胞被称为“活药物”。加入共刺激结构域可增强CAR-T 抗血液肿瘤作用,促进其临床应用。不同共刺激结构域已用于构建CAR-T 并研究抗肿瘤效果,但其影响功能的分子机制报道较少。虽然共刺激结构域在T细胞中的作用已被广泛研究,它们在CAR结构中是否发挥独特功能仍不清楚。本文基于有限文献总结不同共刺激结构域对CAR-T 信号通路的影响,并结合CAR-T 特征推测可能机制。综述有助于理解不同结构域导致抗肿瘤效应差异的分子基础,并为后续干预、增强免疫治疗效果提供参考。

展开英文摘要原文

Chimeric antigen receptor (CAR)-engineered T cells have been defined as 'living drug'. Adding a co-stimulatory domain (CSD) has enhanced the anti-hematological effects of CAR-T cells, thereby elevating their viability for medicinal applications. Various CSDs have helped prepare CAR-T cells to study anti-tumor efficacy. Previous studies have described and summarized the anti-tumor efficacy of CAR-T cells obtained from different CSDs.

However, the underlying molecular mechanisms by which different CSDs affect CAR-T function have been rarely reported. The role of CSDs in T cells has been significantly studied, but whether they can play a unique role as a part of the CAR structure remains undetermined.

Here, we summarized the effects of CSDs on CAR-T signaling pathways based on the limited references and speculated the possible mechanism depending on the specific characteristics of CAR-T cells. This review will help understand the molecular mechanism of CSDs in CAR-T cells that exert different anti-tumor effects while providing potential guidance for further interventions to enhance anti-tumor efficacy in immunotherapy.

论文信息

作者
Zhao W、Yao Y、Li Q、Xue Y、Gao X、Liu X、Zhang Q、Zheng J
第一作者单位
Cancer Institute, the First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.China
通讯作者单位
Cancer Institute, the First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address: sssun@xzhmu.edu.cn.China
文献类型
综述 · 非美国政府资助研究
期刊
Biochemical pharmacology2024 Sep
原文标识
PubMed 39032532 · DOI 10.1016/j.bcp.2024.116439